2809 related articles for article (PubMed ID: 7852053)
1. An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2.
Courtney LP; Phelps JL; Karavodin LM
Immunopharmacology; 1994; 28(3):223-32. PubMed ID: 7852053
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.
Melder RJ; Osborn BL; Riccobene T; Kanakaraj P; Wei P; Chen G; Stolow D; Halpern WG; Migone TS; Wang Q; Grzegorzewski KJ; Gallant G
Cancer Immunol Immunother; 2005 Jun; 54(6):535-47. PubMed ID: 15592670
[TBL] [Abstract][Full Text] [Related]
3. Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2.
Harada M; Matsuzaki G; Shinomiya Y; Kurosawa S; Ito O; Okamoto T; Takenoyama M; Sumitika H; Nishimura Y; Nomoto K
Cancer Immunol Immunother; 1994 May; 38(5):332-8. PubMed ID: 8162615
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the growth of human melanoma metastases in nude mice by melanoma-specific murine monoclonal antibody.
Abdel-Wahab ZA; Darrow TL; Vervaert CE; Giannopoulou AA; Li W; Seigler HF
Surg Oncol; 1992 Apr; 1(2):115-25. PubMed ID: 1341242
[TBL] [Abstract][Full Text] [Related]
5. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
Silagi S; Schaefer AE
J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
[TBL] [Abstract][Full Text] [Related]
6. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
7. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma.
Silagi S; Dutkowski R; Schaefer A
Int J Cancer; 1988 Feb; 41(2):315-22. PubMed ID: 3123404
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of recombinant human interleukin-2: biological features and clinical relevance.
Hänninen EL; Knüver-Hopf J; Atzpodien J
Biotherapy; 1993; 6(4):251-61. PubMed ID: 7517168
[TBL] [Abstract][Full Text] [Related]
9. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.
Krieg C; Létourneau S; Pantaleo G; Boyman O
Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11906-11. PubMed ID: 20547866
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of therapeutic effect of recombinant tumor necrosis factor against B16 mouse melanoma by combination with recombinant interleukin 2.
Urano K; Habu S; Nishimura T
Cytokine; 1993 May; 5(3):224-9. PubMed ID: 8218934
[TBL] [Abstract][Full Text] [Related]
12. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2.
Wojtowicz-Praga S; Verma UN; Wakefield L; Esteban JM; Hartmann D; Mazumder A
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):169-75. PubMed ID: 8811491
[TBL] [Abstract][Full Text] [Related]
13. IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb.
Kamimura D; Sawa Y; Sato M; Agung E; Hirano T; Murakami M
J Immunol; 2006 Jul; 177(1):306-14. PubMed ID: 16785526
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
15. Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma.
Zloza A; Dharmadhikari ND; Huelsmann EJ; Broucek JR; Hughes T; Kohlhapp FJ; Kaufman HL
Cancer Immunol Immunother; 2017 Jan; 66(1):9-16. PubMed ID: 27757560
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.
Ootsu K; Gotoh K; Houkan T
Cancer Immunol Immunother; 1989; 30(2):71-80. PubMed ID: 2598180
[TBL] [Abstract][Full Text] [Related]
17. Nude mouse model to study passive humoral immunotherapy directed against B16 F10 murine melanoma.
Shrayer D; Bogaars H; Gersten D; Hearing V; Maizel A; Wanebo H
J Surg Oncol; 1994 Sep; 57(1):50-6. PubMed ID: 8065154
[TBL] [Abstract][Full Text] [Related]
18. In situ detection of immunocompetent cells in murine B16 melanoma locally treated with interleukin-2 or microwaval hyperthermia.
Nakayama J; Urabe A; Terao H; Taniguchi S; Hori Y
Pigment Cell Res; 1993 Mar; 6(2):111-6. PubMed ID: 8100634
[TBL] [Abstract][Full Text] [Related]
19. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
20. Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases.
Eisenthal A; Lafreniere R; Lefor AT; Rosenberg SA
Cancer Res; 1987 Jun; 47(11):2771-6. PubMed ID: 3494504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
